LOS ANGELES – For the 250 million people who pour a cup of coffee each morning, the habit has long occupied the hazy territory between pleasure and nutrition, more ritual than medicine. A study published July 1 in Clinical Gastroenterology and Hepatology – the largest of its kind ever conducted – suggests that territory has been mismapped. Researchers at Cedars-Sinai Medical Center, tracking nearly 355,000 people over 13 years, found that regular coffee drinkers had dramatically lower rates of liver cancer, cirrhosis, and liver-related death than those who drank none. For the first time, MRI scans of those drinkers’ livers showed why.
The numbers are striking even by clinical-trial standards. Participants who consumed five or more cups of coffee per day had a 47 percent lower risk of developing liver cancer, a 32 percent lower risk of cirrhosis, and a 42 percent lower risk of dying from a liver-related cause, compared to non-drinkers. The study, based on 354,957 UK Biobank participants followed for a median of 13 years, confirmed those associations in a population more than ten times larger than most prior studies on this question. What separates the Cedars-Sinai analysis from the research that preceded it is not only scale. When investigators examined MRI scans from a subset of participants, coffee drinkers showed measurably less liver fat, less iron accumulation, less fibrosis, and less inflammation than those who did not drink coffee. The correlation that earlier research identified as statistical association now had a visible biological fingerprint.
“Previous studies suggested that coffee might benefit the liver, but most were smaller or looked at only one piece of the puzzle,” said Dr. Hyunseok Kim, the study’s lead author and an assistant professor of medicine at Cedars-Sinai Health Sciences University, in remarks accompanying the publication. Blood protein analyses in the same dataset showed higher levels of proteins indicating normal liver function in regular coffee drinkers, and lower levels of markers associated with scarring and inflammation. The pattern held across men and women, across age groups, and across the full dose range – from one cup per day, where benefits began to appear, to five or more, where the protective association was strongest.
The finding about decaffeinated coffee may be the most consequential result in the paper. Because people who drank decaffeinated coffee showed liver-protective associations similar to those drinking caffeinated varieties, the caffeine molecule itself cannot be the primary active agent. The researchers wrote in Clinical Gastroenterology and Hepatology that caffeine is “unlikely to be the only active component,” and that other naturally occurring compounds in coffee – its polyphenols, diterpenes, and chlorogenic acids – appear to carry or share the protective effect. Which specific compound or combination drives the biological changes that the MRI scans revealed is not yet known.
That gap is now Cedars-Sinai’s next research question. Dr. Shelly Lu, Director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai, said the team’s focus going forward is identifying the specific compounds responsible for these liver associations. The practical implication of that work would be significant: if an active molecule can be isolated and characterized, researchers could study whether it can be extracted, concentrated, or delivered in a form that does not require drinking five cups a day to access its protective potential.
The public health stakes attached to this research are not abstract. Liver cancer – specifically hepatocellular carcinoma, the dominant form – kills approximately 700,000 people globally each year and is among the cancers with the steepest rise in incidence in the United States over the past three decades. That rise tracks the epidemic of non-alcoholic fatty liver disease, which has become a leading cause of liver transplant listings in the country. Cirrhosis, the progressive scarring of liver tissue that precedes liver failure and cancer, currently affects roughly 4.5 million Americans, many of whom have no symptoms until the damage is advanced. Interventions that operate before disease is established – and that large populations are already doing without any medical instruction – carry unusual promise.
Dr. Ju Dong Yang, Medical Director of the Liver Cancer Program at Cedars-Sinai and the study’s senior author, was precise about what the findings do and do not license. Coffee, he said, should complement established prevention strategies – maintaining a healthy weight, limiting alcohol, treating and screening for hepatitis, controlling diabetes – rather than substitute for them. The study’s observational design means it cannot demonstrate causation; people who drink five cups of coffee a day may differ from non-coffee drinkers in other ways that also affect liver health, and no amount of statistical adjustment fully resolves that uncertainty. The team would not recommend that anyone begin drinking coffee solely on the basis of these findings.
Identifying common consumables or approved compounds that affect cancer risk has become one of the more active threads in contemporary clinical research. Earlier this month, a team at the University of California, Los Angeles found that two drugs already approved for arthritis and multiple sclerosis – leflunomide and teriflunomide – can halt the growth of small cell neuroendocrine cancers in laboratory models, exploiting a molecular dependency that a genome-wide CRISPR screen uncovered. The pattern of existing, well-characterized compounds disclosing effects their original trials never measured is not unusual in clinical research; it is the basis on which most drug repurposing work operates. Whether the compounds in coffee prove similarly exploitable – an active molecule that can be separated from the beverage and studied in isolation – is the question Dr. Lu and her colleagues at Cedars-Sinai have now set out to answer.
The Cedars-Sinai study does not prove that coffee prevents liver disease. What it does, for the first time at a scale that commands serious clinical attention, is confirm that the liver of someone who drinks coffee regularly looks structurally different from the liver of someone who does not. Less fat. Less iron. Less scarring. Less inflammation. Thirteen years of MRI and protein data from 354,957 people. The specific compound or compounds responsible remain unidentified, and the causal mechanism unconfirmed. Those are not small unknowns. But the data’s direction, repeated across cohort sizes that few medical studies ever approach, is now on record.
